A 3-day regimen of azithromycin (500 mg once daily) and a 10-day regimen of co-amoxiclav (625 mg three times daily) were compared in a double-blind study of 67 patients with acute infectious exacerbations of chronic bronchitis (AIECBs, n = 54), acute bronchitis {n = 7), or pneumonia (n = 6). In patients treated with azithromycin, satisfactory clinical responses (cure or improvement) were seen in 24/28 (86%) patients with AIECBs, 2/4 (50%) with acute bronchitis and 2/2 (100%) with pneumonia. Responses were satisfactory in 24/26 (92%), 4/4 (100%) and 4/4 (100%) patients, respectively, receiving co-amoxiclav. Streptococcus pneumoniae and Haemophilus influenzae were the commonest pathogens isolated at baseline. At the end of treatment, baseline pathogens were eradicated in 9/10 microbiologically-assessable patients treated with azithromycin and in 10/10 treated with co-amoxiclav. Adverse events related or possibly related to treatment occurred in five patients in each treatment group; the majority of these events affected the gastrointestinal system. One patient in each treatment group discontinued therapy because of adverse events. The study, therefore, demonstrates that 500 mg azithromycin administered once daily for 3 days is as efficacious and well tolerated as co-amoxiclav given three times daily for 10 days in the domiciliary treatment of adults with acute lower respiratory tract infections.
Introduction
The semisynthetic azalide antibiotic azithromycin is structurally related to the macrolide erythromycin (Bright et al., 1988) , but has characteristics that overcome several problems, associated with the use of the original macrolide, in the treatment of lower respiratory tract infections, most notably erythromycin's poor activity against Haemophilus influenzae and other Gram-negative bacillary organisms. Not only does azithromycin possess superior activity to erythromycin against H. influenzae (Aronoff, Laurent & Jacobs, 1987; Retsema et al., 1987) , but it also has excellent activity against other pathogens commonly implicated in lower respiratory tract infections, including Streptococcus pneumoniae and Moraxella catarrhalis (Retsema et al., 1987) . Other characteristics of azithromycin also point to the agent's role in the treatment of lower respiratory tract infections. The principal features of azithromycin's pharmacokinetic profile are its rapid penetration of tissue and the ability to maintain high concentrations in tissues several days after dosing (Foulds, Shepard & Johnson, 1990) . Following oral administration, high levels of azithromycin are achieved and maintained in, for example, bronchial mucosa, epithelial lining fluid, sputum and alveolar macrophages (Baldwin et al., 1990; Harf et al., 1992) . Local concentrations of azithromycin are further increased, as migrating phagocytes transport the compound to sites of infection and release it in response to the presence of pathogens (Gladue et al., 1989; Panteix et al., 1993) . Extrapolation of the pharmacokinetic data has indicated that a 3-day, once-daily regimen of azithromycin would be effective in the treatment of lower respiratory tract infections (Foulds & Johnson, 1993) .
The aim of the present study was to evaluate the clinical and microbiological efficacy of azithromycin and compare the azalide with well-established therapy. Penicillins are still the pre-eminent treatment for lower respiratory tract infections. When these agents were first introduced resistance was rare, but it is now encountered with ever-increasing frequency and may lead to treatment failure. Penicillin resistance or tolerance has developed in some strains of S. pneumoniae, although amoxycillin, the oral penicillin with the greatest activity against pneumococci, can still be effective against such infections provided that the proportion of strains showing high-level resistance is low. Amoxycillin alone is, however, generally ineffective when bacterial resistance is due to /?-lactamase production, as is frequently the case with H. influenzae and M. catarrhalis. To overcome this problem, formulations containing a /?-lactamase inhibitor, such as amoxycillin plus clavulanic acid (co-amoxiclav) or ampicillin plus sulbactam, are widely used as first-line treatment for lower respiratory tract infections. However, resistance in H. influenzae and M. catarrhalis is sometimes mediated by mechanisms other than /Mactamase production and, in such cases, even formulations containing a /Mactamase inhibitor may not prove efficacious if given empirically.
Patients and methods

Patient selection
Men and women outpatients (18 years or older) with acute bronchitis, acute infectious exacerbations of chronic bronchitis (AIECBs) or pneumonia were recruited into the study at seven centres in Belgium. The diagnosis was made on the basis of clinical signs and symptoms, and chest radiology. For a diagnosis of acute bronchitis, a patient had to produce purulent sputum and to have at least one of the following features: fever (^38 C); leucocytosis ^10 x 1O'/L; or cough, dyspnoea, rales, rhonchi and/or wheezing. The criteria for a diagnosis of chronic bronchitis were a history of chronic or recurrent productive cough, present on most days for a minimum of 3 months, for at least 2 successive years. Acute exacerbations were denned in terms of symptoms, as described by Anthonisen et al. (1987) . Patients were considered to have pneumonia if, in addition to a chest X-ray showing a new pulmonary infiltrate, they had a productive cough, a change in the character of their sputum with < 10 epithelial cells per low-power field and ^ 25 polymorphonuclear leucocytes per high-power field, sputum culture of pathogenic organisms, a body temperature of 38°C or more at least twice within a 24-h period, and/or an increased leucocyte count ( > 10 x 1O'/L). Patients with pneumonia, however, were not admitted to the study if they were older than 75 years, had consolidation of more than one entire lung lobe, had a WBC of 30 x 10'/L or higher, required oxygen, or had a positive blood culture.
Any patient with a terminal illness was excluded from the study. Also excluded were patients with any condition that would preclude study completion and those suffering from infectious mononucleosis, any condition likely to affect gastrointestinal absorption of the antimicrobial agent, or a hepatic disorder with serum transaminase levels more than three times greater than the upper limit of the normal range. Women were not enrolled if they were pregnant, breast-feeding, or of child-bearing potential and not using adequate contraception (oral contraception or a barrier method). Concurrent medication with ergotamine, cyclosporin, antacids (except H 2 -antagonists), or digitalis glycosides was not permitted. Patients hypersensitive to azithromycin, other macrolides, or /Mactam antibiotics were also excluded. Other reasons for exclusion were concurrent infections requiring additional antimicrobial therapy, Gram staining that suggested the presence of an organism against which the study antibotics would be ineffective, and drug or alcohol dependency. In addition, patients were not enroled if they had received another antimicrobial agent in the previous 2 weeks, unless treatment was a microbiologically-documented failure, another investigational drug in the previous month, or if they had already participated in the current study.
The approval of the institutional review board was obtained for this study and each patient gave written informed consent prior to participation.
Treatment
Patients were randomly assigned to treatment with azithromycin (Pfizer), one 500-mg tablet once daily on 3 consecutive days, or co-amoxiclav (Augmentin, Beecham Research) 625 mg three times daily for 10 days. Blinding of the study was maintained with matched placebo tablets: azithromycin group patients received placebo co-amoxiclav tablets three times daily for 10 days and co-amoxiclav patients placebo azithromycin tablets for the first 3 days of therapy.
Assessment of clinical efficacy
The first day of study drug treatment was defined as day 1. Clinical symptoms were recorded before treatment on day 1, and changes were monitored on days 5 ± 2 and 14 ± 2. At the assessment on day 14 ± 2 clinical response was classified as cure, improvement, failure, or relapse. Cure was defined as the disappearance of all acute pretreatment clinical signs and symptoms, although in patients with pneumonia the chest X-ray could still show some signs of infiltrates, and patients with AIECBs would still show symptoms of their underlying condition. Improvement was the partial disappearance or improvement of pretreatment signs and symptoms. Failure was considered to have occurred when there was no change, or worsening of the signs and symptoms of infection present before treatment. A patient was classed as having relapsed if pretreatment signs and symptoms initially improved or disappeared, but subsequently returned or worsened, with the need for additional antibiotic therapy.
Assessment of bacteriological efficacy
Sputum samples were obtained for microbiological culture before therapy and, where possible, after completion of treatment (day 14 ± 2). Organisms were isolated and identified by a standard microbiological method and susceptibility testing was performed by a disc diffusion method (National Committee for Clinical Laboratory Standards, 1985) . Gram staining was performed on sputum samples and the numbers of leucocytes determined.
Microbiological response to treatment assessed on day 14 ± 2 was recorded and categorized as eradication or persistence. Eradication was defined as the elimination of baseline pathogen(s), or the inability to obtain a sample for culture following resolution of the patient's cough. Persistence was the presence of baseline pathogen(s) at the end of treatment.
Safety
At every visit, any adverse event, either reported spontaneously by the patient or observed by the investigator, was recorded and classified according to its severity and relationship to treatment. Haematology, blood chemistry and urinalysis tests were performed on all patients on entry to the study and were repeated on day 14 ± 2.
Statistical analysis
The clinical response for the two treatment groups was compared by the Cochran-Mantel-Haenszel test based on Ridit scores. Safety data for the two groups were compared using the chi-squared or Fisher's exact test as appropriate. The statistical tests were all two-tailed and were performed at the 0.05 significance level.
Results
In total, 78 patients were enrolled in this study; 41 patients were randomly assigned to receive azithromycin and 37 to co-amoxiclav treatment. Table I summarizes the patients' demographic characteristics; there were no marked demographic differences between the patients assigned to the two treatment groups, and the majority of the patients were between 56 and 75 years old. Acute infectious exacerbations of chronic bronchitis were the most frequently encountered infections in this study, with 28 of these patients assigned to azithromycin treatment and 26 patients to the co-amoxiclav group being clinically evaluable.
Of the 78 patients enrolled, 11 (seven in the azithromycin and four in the co-amoxiclav group) were not clinically evaluable. Reasons for exclusion of patients from clinical evaluation were as follows: failure to meet entry criteria (one patient in each treatment group); failure to observe the protocol (three azithromycin and two co-amoxiclav patients); and treatment incomplete due to an adverse event not necessarily related to treatment (three azithromycin and one co-amoxiclav patients). At the end of treatment, 26 (ten azithromycin and 16 co-amoxiclav) patients were evaluated for bacteriological response. Patients were excluded from bacteriological evaluation for the following reasons: entry criteria not met (one azithromycin and two co-amoxiclav patients): protocol violation (three azithromycin and one co-amoxiclav patients); adverse event, not necessarily related to treatment (three azithromycin and one co-amoxiclav patients); no baseline pathogen (17 azithromycin and 14 co-amoxiclav patients); resistant or inappropriate pathogen at baseline (three patients in each treatment group); no baseline culture (one azithromycin patient); and susceptibility not assessed (three azithromycin patients).
Clinical and microbiological efficacy
Overall, a satisfactory clinical response (cure or improvement) was recorded in 28/34 (82%) patients who received azithromycin and in 31/33 (94%) patients treated with co-amoxiclav, and of these patients, 23/34 (68%) and 22/33 (67%), respectively were classed as cured (Table II) . Satisfactory clinical responses were recorded in 24/28 (86%) AIECB patients treated with azithromycin and in 24/26 (92%) who had received co-amoxiclav. Three (11%) azithromycin-and one (4%) co-amoxiclav-treated patients were considered to be treatment failures, and one patient in each group was deemed to have relapsed. There were four clinically evaluable patients with acute bronchitis in P. Gris the azithromycin group, one of whom was cured and one improved following treatment.
Of the three patients with acute bronchitis receiving co-amoxiclav, two were cured and the other improved. Six patients with pneumonia (two treated with azithromycin and the remainder with co-amoxiclav) were clinically evaluable. In the azithromycin group, both patients were classed as clinically cured, whereas one pneumonia patient treated with co-amoxiclav was classed by the investigator as being clinically cured and the remaining three were improved. At day 21 after the start of treatment, three patients assigned to azithromycin and seven to co-amoxiclav treatment who were considered improved at the end of treatment assessment on day 14 + 2 were re-evaluated. Of these patients, two from the azithromycin group were classed as cured and the other remained improved. Six of the patients returning from the co-amoxiclav group were cured; the remaining patient had relapsed.
All but one of the baseline pathogens were eradicated in ten microbiologicallyassessable patients in the azithromycin group (Table III) and all 16 respiratory pathogens were eradicated from patients treated with co-amoxiclav (Table III) . S. pneumoniae persisted in one AIECB patient treated with azithromycin, although this patient was considered to be clinically improved. Another AIECB patient receiving azithromycin was considered to have relapsed, although the baseline pathogen (H. influenzae) was eradicated.
Safety
A total of eight adverse events that were considered by the investigator to be related or possibly related to study treatment were experienced by five (12%) patients receiving azithromycin (Table IV) . Among the co-amoxiclav-treated patients, five (14%) experienced a total of seven such events. The proportion of patients with treatment-related adverse events was not significantly different between treatment groups {P = 0.541). All events, except one in the azithromycin group (mild taste perversion), affected the gastrointestinal system. In the co-amoxiclav group, three adverse events were considered to be severe; the remainder were of mild or moderate 1/1 3/3 1/1 AIECB, Acute infectious exacerbation of chronic bronchitis.
•Cure or improvement; "one patient was considered to have relapsed. severity, as were all the events in the azithromycin group. Possible or probable treatment-related adverse events (nausea and/or vomiting) led to one patient in each group discontinuing treatment. There were no statistically significant differences in demographic/baseline characteristics, clinical response, incidence of adverse events, withdrawals and laboratory test abnormalities between treatment groups.
Discussion
This study demonstrated that once-daily dosing with 500 mg azithromycin for 3 days was as clinically efficacious as a 10-day course of co-amoxiclav of 625 mg given three times daily in the treatment of lower respiratory tract infections. The patients within the study were predominantly middle-aged or older and suffering from AIECBs; most patients were severely ill. The results of the present study are consistent with those of previous trials comparing 3-day azithromycin with the longer-duration course of co-amoxiclav in the treatment of acute lower respiratory tract infections (Hoepelman et al., 1993; Sevieri, Roggi & Monacci, 1993) . In addition, a satisfactory clinical response in this study correlated with the elimination of pathogens in those patients from whom sputum samples were obtainable and infecting microorganisms identified.
Tolerance of azithromycin therapy by the patients was good, with a comparable incidence of adverse events that were considered possibly or probably related to treatment being experienced by patients treated with either azithromycin or co-amoxiclav. Thus the present study, in which a complete course of azithromycin therapy was achieved by once-daily dosing over 3 days, did not result in any compromise in tolerability. Other studies have also demonstrated that azithromycin is well tolerated. Hopkins (1994) , for example, in reviewing the safety data from more than 4000 adults who had received a total dosage of 1.5 g azithromycin over 3-5 days for the treatment of a range of diseases, including lower respiratory tract infections, showed that the azalide was comparable to established comparative agents in terms of the incidence of adverse events.
Poor compliance with anti-infective regimens more than 7 days in length and which involve multiple daily dosing has been acknowledged as a problem for some years (Gatley, 1968) and can result in an unsatisfactory clinical outcome (Colcher & Bass, 1972) with the need for a further course of antibiotic therapy. Duration and frequency of dosing are among the most important of many factors affecting compliance (Greenberg, 1984; Cockburn et ai, 1987) ) and an anti-infective agent with a short course of treatment and once-daily dosing should improve patient compliance, and thus clinical outcome. Outside the clinical trial setting, where monitoring of patients generally results in better compliance than in clinical practice, azithromycin should be more effective than antimicrobials with longer and more complex treatment regimens, as patients may be more likely to comply to therapy.
In conclusion, this study confirms that 500 mg azithromycin administered once daily for 3 days is a valuable alternative to co-amoxiclav which is given three times daily for 10 days in the treatment of patients with lower respiratory tract infections. Azithromycin's simplified three-dose course of treatment may have the advantage that it is more acceptable to outpatients who are less likely to complete a 30-dose regimen.
